Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
Lead Sponsor:
BioWest Therapeutics Inc
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
Eligibility Criteria
Inclusion
- The patient must be 18 to 65 years of age, inclusive.
- Primary diagnosis of chronic HCV infection.
Exclusion
- Patients who did not respond or relapsed following therapy with interferon.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00157534
Start Date
October 1 2004
End Date
August 1 2005
Last Update
September 12 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.